What happened to baricitinib’s new ORAL Surveillance? Save
We are missing some key data which we were promised, and we want and deserve to know how this story ends.
The late breaking abstracts at EULAR were jam packed with highly provocative data. It was the first appearance of the BE BOLD study, showing one excellent biologic DMARD in PsA completely outperforming another excellent one. Baricitinib for new-onset PMR, nipocalimab and sirolimus in SLE, nanobodies at the sacroiliac joints, trispecific T cell engagers, even cord NK cells.
Buried at the end, in a seven minute abstract with no real time for questions, was possibly one of the most potentially consequential abstracts of them all: the headline data from the RA-BRIDGE/BRANCH study.
These paired studies (geographically separate but identically intentioned) were the missing piece of the puzzle for JAK inhibitor safety. They were to address a phase 4 postmarketing requirement set in 2018 by the FDA for the manufacturer of baricitinib to address potential safety concerns, in a very similar way to ORAL Surveillance was set for the manufacturer of tofacitinib. It was meant to address the risk of thrombosis from baricitinib versus TNF inhibitors, something which we have understood to a reasonable extent to launch, and had come to expect and accept. The mandate was slightly wider: “The trial should be of sufficient size and duration to evaluate safety events of interest, including arterial and venous thrombosis, cardiovascular adverse events, opportunistic infections, and malignancy”.
This was before many people were at all aware of the presence of the ORAL Surveillance postmarketing requirement, let alone expecting a cardiovascular and cancer signal in RA patients with increased cardiovascular risk. JAK inhibitors had been adopted globally, and with gusto in many parts of the world. Their advantages were becoming apparent and real-world safety data kept on being reassuring. We were not to know the chaos that would emerge at ACR Convergence in 2021, when the results would raise very different questions.
It was after that meeting that the baricitinib postmarketing requirement, due on October 2026, came firmly into attention. Was the ORAL Surveillance problem, captured by a rare phase 4 safety signal RCT, an individual drug issue or a class issue? Was this a problem for just tofacitinib, or JAK inhibitors as a whole?
These data were meant to be presented at this year’s ACR meeting, albeit selected only as a poster. Certainly, the rheumatology community had had a seven minute preview of the headline data in June at EULAR, and there was real reason for hope: in this VTE risk-enriched population - similar but not quite the same as ORAL Surveillance - baricitinib conference a risk of MACE of HR 1.06 (0.638-1.760), and malignancy of HR 1.27 (0.853-1.891). This exoneration seemed an enormous boon for the future of JAK inhibitors - and while the tofacitinib patent had expired, with the baricitinib patent expiring in 2032 and upadacitinib in 2033, the question of individual drug or class effect surely represented a multibillion dollar commercial question, if not one of the most consequential drug safety questions of our time, in RA but in many other diseases which need JAK inhibitors more.
So why was the poster withdrawn?
I do not know and I have not asked the manufacturer, but I hope it is merely a pause for breath rather than an end. Notably, the final study report was submitted in December 2025, and on October 9, 2026, the FDA deemed the postmarketing requirement fulfilled and approved a label update that added the direct comparison with TNF inhibitors to the boxed warning. It appears that, less than two weeks later, the poster was withdrawn.
Is it merely a late abandonment in response to only being selected as a poster? Is this an internal review and pivot, and why would presenting a poster get in the way of that?
All I know is that I hope that this is not the last we see of it, and it seems likely that we will get plenty more data in the future, although an abstract withdrawal does not portend well on that front. We need the opportunity to appreciate the full data in due course, and understand its very real and important implications for JAK inhibitor safety.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.